The high efficacy of luliconazole against environmental and otomycosis *Aspergillus flavus* strains

Maryam Moslem¹,², Ali Zarei Mahmoudabadi¹,²*

¹Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
²Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

Received: November 2019, Accepted: February 2020

ABSTRACT

Background and Objectives: Luliconazole is currently confirmed for the topical therapy of dermatophytosis. Moreover, it is found that luliconazole has *in vitro* activity against some molds and yeast species. The aim of the present study was to evaluate the efficacy of luliconazole in comparison to routine used antifungals on clinical and environmental isolates of *Aspergillus flavus*.

Materials and Methods: Thirty eight isolates of *A. flavus* (18 environmental and 20 clinical isolates) were detected based on morphological and microscopic features and also PCR-sequencing of β-tubulin ribosomal DNA gene. All the isolates were tested against luliconazole, voriconazole, amphotericin B and caspofungin. Minimum inhibitory concentration (MIC), MIC₅₀, MIC₉₀ and MIC Geometric (GM) were calculated using CLSI M38-A2 protocol for both environmental and clinical isolates.

Results: Luliconazole with extremely low MIC range, 0.00049-0.00781 μg/mL and MIC GM 0.00288 μg/mL showed very strong activity against both clinical and environmental *A. flavus* isolates. Moreover, voriconazole inhibited 100% of isolates at defined epidemiological cutoff values (ECV ≤ 2 μg/ml). 50% and 27.8% of clinical and environmental isolates of *A. flavus*, were resistant to caspofungin, respectively. Whereas, all the isolates were found to be resistant to amphotericin B.

Conclusion: The analysis of our data clearly indicated that luliconazole (with MICGM 0.00244 μg/ml for clinical and 0.00336 μg/ml for environmental isolates) had the highest *in vitro* activity against *A. flavus* strains.

Keywords: Antifungal susceptibility; Luliconazole; Amphotericin B; Voriconazole; Caspofungin; *Aspergillus flavus*

INTRODUCTION

Luliconazole, (-)-(E)-[(4R)-4-(2, 4-dichlorophenyl)-1-3-dithiolan-2-ylidene] (1H63imidazol-1-yl) acetonitrile, is a new synthetic imidazole antifungal. Luliconazole was firstly synthesized by Nihon No- hyaku Co Ltd in Japan in 2005 and similar to other common azoles, it is effective on ergosterol biosynthesis with fewer side effects and greater potency (1, 2). Luliconazole initially available as topical cream (LUZU) 1% for dermatophytosis and solution 10% for onychomycosis (1, 3, 4). A very low minimum inhibitory concentration (MIC) of luliconazole for dermatophytes, *Candida*, *Fusarium* and *Aspergillus* species has been reported (2, 5-7).

Amphotericin B has remained a Gold standard for the treatment of several invasive fungal infections for several decades (8, 9). Moreover, its fungicidal activ-
MATERIALS AND METHODS

Clinical and environmental isolates of Aspergillus flavus. Twenty clinical isolates of A. flavus previously collected from otomycosis, were identified by morphological and microscopic characteristics and preserved in medical mycology laboratory affiliated to Ahvaz Jundishapur University of Medical Sciences. Furthermore, 16 strains of A. flavus collected from different areas of Ahvaz in autumn and winter 2018 using by Quick Tack air sampler (SKC 338.4530). In addition, two isolates of A. flavus were isolated from soil samples. All 38 A. flavus isolates were subcultured on Sabouraud dextrose agar (SDA) (Merck, Germany) supplemented with 0.05% chloramphenicol (Merck, Germany), and incubated at 29 °C for 5 days. Then, strains were identified at the species level according to their macroscopic and microscopic morphological features. Color and texture of the A. flavus colonies were yellow green and cottony or powdery, respectively. Microscopic morphology include roughly and spiny conidiophores, loosely radiate phialides on most of vesicles and phialides to form uniseriate or biseriate were confirmed as A. flavus (23). This was approved by ethical committee of Ahvaz Jundishapur University of Medical Sciences (IR.AJUMS.REC.1398.263).

Molecular identification and sequencing. All isolates were subcultured on SDA and incubated at 29 °C for 3 days. Then, approximately, 300 mg of mycelia collected in microtubes containing 300 μL of lysis buffer and 50 mg glass bed (Sigma - Aldrich, USA) and were put at -20 °C for 24 h. Microtube contents homogenized by a SpeedMill PLUS Homogenizer (Analytikjena, Germany) were extracted using phenol-chloroform-isoamyl alcohol (Sigma - Aldrich, Germany) (24). PCR was performed, using primers Bt2a (5’-GGTAACCAAATCGGTGCTGCTTTC-3’) and Bt2b (5’-ACCCTCAGTGTAGTGACCCTTG-GC-3’) for all isolates (25). The PCR products electrophoresed on agarose gel 1.2% and 500-600 bp bands were considered as A. flavus. Furthermore, 12 and 10 PCR products from environmental and clinical isolates were randomly selected and presented for nucleotide sequencing. Nucleotide sequence data aligned by Mega 6 Software were blasted using GenBank database (100% similarity). Finally, the nucleotide sequence data were submitted to the GenBank database.

Antifungal agents and antifungal assay. A solution of luliconazole (APIChem Technology, China), voriconazole (Sigma-Aldrich, Germany), caspofungin (Sigma-Aldrich, Germany), and amphotericin B (Sigma-Aldrich, Germany) were prepared in dimethyl sulfoxide (DMSO) (Merck, Germany) at 0.0001-0.125, 0.0625-8, 0.0312-4 and 0.5-64 μg/mL, respectively. In vitro antifungal susceptibility testing of 38 A. flavus isolates was performed using CLSI M38-A2 protocol (26). Briefly, a spore suspension of tested isolates was prepared in sterile 0.85% saline supplemented with 1% Tween 20 (Merck, Germany) and adjusted to 0.5 McFarland standard. Then, each microplate well was filled with 100 μL of each suspension and 100 μL of a serial dilution of each anti-

ity against the most of fungal isolates has been confirmed in vitro (10-12). Due to amphotericin B side effects and increased resistance to it, new antifungals for the treatment of disseminated mycosis were developed. During 2-3 past decades, new antifungals including, voriconazole, posaconazole and caspofungin were licensed for the treatment of invasive aspergillosis (7, 8). So that, voriconazole was presented as the first-line antifungal for invasive aspergillosis therapy (13, 14). Also, caspofungin is recommended for invasive aspergillosis in AIDS patients (5). The clinical resistance of Aspergillus species to echinocandins like caspofungin is very low (15).

Aspergillus flavus not only has the ability to causes primary infections in immunocompetent (16, 17), but also cause invasive infections in chemotherapy users, invasive therapy, immunocompromised patients, organ transplant and hematopoietic stem cell recipients (8, 14). In addition, A. flavus is one of the most important otomycosis agents (18). On the other hand, intrinsic and acquired azole - resistance have predominantly been reported for several Aspergillus species comprise A. fumigatus, A. flavus, A. niger, A. terreus and A. lentulus in vitro (2, 13, 19, 20). Moreover, resistant to amphotericin B in invasive aspergillosis has been reported for different Aspergillus species including A. flavus (21, 22). Due to limited information about the activity of luliconazole on A. flavus (7), in the present study we compared the efficacy of luliconazole vs. amphotericin B, voriconazole, and caspofungin against the clinical and environmental strains of A. flavus.
fungals. Microtiter plates were incubated at 35 °C for 24 h in humid incubator. Finally, MIC and minimum effective concentrations (MEC) were detected. The MIC$_{50}$, MIC$_{90}$ and MIC$_{\text{Geometric GM}}$ were also calculated. The susceptibility (sensitive or resistant) was determined based on epidemiological cutoff values (ECVs) for amphotericin B (4 µg/mL), voriconazole (2 µg/mL) and caspofungin (0.5 µg/mL) (27).

**Statistical analysis.** The distribution of MIC between clinical and environmental *A. flavus* isolates was analyzed by χ² test and P values < 0.05 were considered statistically significant.

**RESULTS**

In this study, according to microscopic and morphological features, 38 isolates of *A. flavus* were confirmed. Moreover, 22 of 38 isolates were randomly selected, sequenced and analysed. All sequenced data were deposited in Genbank (accession numbers; clinical isolates (10 isolates): LC440566 to LC440575; environmental isolates (12 isolates): LC457998 to LC458009). Table 1 presents the results of the *in vitro* susceptibility tests of four antifungal agents against 38 clinical and environmental isolates of *A. flavus*. As shown, luliconazole was exhibited a very low MIC against all tested *A. flavus* isolates, MIC = 0.00049-0.00781 µg/mL for clinically and MIC = 0.00195-0.00781 µg/mL for environmental isolates. Furthermore, as shown MIC$_{\text{GM}}$ for clinical and environmental isolates was 0.00244 µg/mL and 0.00336 µg/mL, respectively.

Although, the MIC range amphotericin B for environmental was lower (8-32 µg/mL) than clinical isolates (16-64 µg/mL), all strains (100%) were resistant to antifungal. Both clinical and environmental isolates of *A. flavus* inhibited at MEC range 0.0625-4 µg/mL of caspofungin, but resistant to caspofungin was more common among clinical isolates (50%) than environmental isolates (27.8%). The MIC range voriconazole for clinical and environmental isolates of *A. flavus* were 0.0625-1 and 0.125-2 µg/mL, respectively. As a results, 100% of isolates (environmental and clinical isolates) were sensitive to voriconazole.

All isolates were found to be resistant to amphotericin B, whereas all clinical and environmental strains were sensitive to voriconazole. Also, we did not found any statistically significant difference between clinical and environmental strains and resistant to caspofungin (*P* = 0.161713). In this study, only 10 (50%) and 5 (27.8%) clinical and environmental isolates of *A. flavus* were resistant to caspofungin, respectively. Moreover, it is found that there is a statistically significant difference between resistant to caspofungin and amphotericin B (*P* < 0.00001) and voriconazole and caspofungin (*P* = 0.000082). Resistance to two different classes of antifungals was only observed in amphotericin B and caspofungin (15 cases) (Table 2).

**DISCUSSION**

*Aspergillus flavus* is a saprophytic filamentous fungus with a high ability for causing different aspergillosis infections such as sinusitis, keratitis, invasive aspergillosis, aspergillum, and otomycosis (19, 28). According to European Conference on Infections in Leukaemia (ECIL-6) guideline, voriconazole or isavuconazole are the first-line treatment of invasive aspergillosis in immunocompromised patients (29), whereas, in some cases the use of amphotericin B, is associated with treatment failure (21, 30).

Luliconazole was primarily presented for the treatment of onychomycosis, tinea pedis and tinea corporis by food and drug administration (FDA) (3, 4, 27), however it was recently found that it displays an excellent activity against several molds (*Aspergillus* and *Fusarium* species), yeasts (*Candida*) and dematiaceous fungi (2, 5-7, 31, 32). Luliconazole has a very low MIC against dermatophytes including *Trichophyton rubrum*, *T. mentagrophytes*, *T. tonsurans* and *Epidermophyton floccosum* (33). In the present study a novel antifungal drug, luliconazole, was used for the susceptibility evaluation of clinical and environmental *A. flavus* isolates *in vitro*.

Luliconazole was recently shown a potent *in vitro* activity against *Aspergillus* species including *A. fumigatus* (2), *A. terreus* (5), *A. flavus* (7) and *A. niger* complex (34) in comparison with other routine antifungal drugs. However, there is no data about the efficacy of luliconazole on *A. flavus* with otomycosis sources. In the present study, the strains of *A. flavus* isolated from otomycosis as well as environmental sources. In the present study, the strains of *A. flavus* isolated from otomycosis as well as environmental sources were tested against luliconazole and the extremely low MICs (0.00049-0.00781 µg/mL) were obtained. Luliconazole with MIC$_{\text{GM}}$ = 0.00288 µg/
Table 1. The antifungal susceptibility pattern of *Aspergillus flavus* isolates

| *Aspergillus flavus* | Antifungal | Minimum inhibitory concentration (μg/mL) | R (%) | %ECV* |
|---------------------|------------|----------------------------------------|-------|-------|
|                     |            | MIC | MIC_{50} | MIC_{90} | MIC_{GM} |       |       |
| Clinical isolates (20) | LUL       | 0.00049-0.00781 | 0.00195 | 0.00391 | 0.00244 | ND   | ND   |
|                     | AMB       | 16-64 | 32 | 64 | 44 | 20 (100) | 0.0% |
|                     | CASb      | 0.0625-4 | 0.25 | 2 | 0.24 | 10 (50) | 50% |
|                     | VRC       | 0.0625-1 | 0.125 | 0.5 | 0.76 | 0 (0.0) | 100% |
| Environmental isolates (18) | LUL | 0.00195-0.00781 | 0.00391 | 0.00391 | 0.00336 | ND | ND |
|                     | AMB       | 8-32 | 32 | 32 | 24.4 | 18 (100) | 0.0% |
|                     | CASb      | 0.0625-4 | 0.25 | 4 | 0.44 | 5 (27.8) | 72.2% |
|                     | VRC       | 0.125-2 | 0.5 | 1 | 0.5 | 0 (0.0) | 100% |
| All isolates (38) | LUL       | 0.00049-0.00781 | 0.00195 | 0.00391 | 0.00288 | ND | ND |
|                     | AMB       | 8-64 | 32 | 64 | 33.8 | 38 (100) | 0.0% |
|                     | CASb      | 0.0625-4 | 0.25 | 1 | 0.55 | 15 (39.5) | 60.5% |
|                     | VRC       | 0.0625-2 | 0.25 | 0.5 | 0.34 | 0 (0.0) | 100% |

LUL, Luliconazole; AMB, Amphotericin B; CAS, Caspofungin; VRC, Voriconazole; GM, Geometric mean; R, Resistance; ND, not determined (no ECVs were available).

* %MICs less than or equal to than the epidemiologic cutoff values (ECVs) (ECV = 4 μg/ml for amphotericin B, 2 μg/ml for voriconazole, 0.5 μg/ml for caspofungin.

* Minimum effective concentration (MEC), MEC_{50}, MEC_{90} and MEC_{GM} were calculated for *Aspergillus flavus*.

Table 2. The susceptibility pattern of *Aspergillus flavus* isolates

| Isolates | Number | LUL (μg/mL) | VOR | AMP | CAS |
|----------|--------|-------------|-----|-----|-----|
| Clinical isolates (20) | 20 | 0.00781 | S | R | R |
| A. flavus | 1 | 0.00781 | S | R | R |
| A. flavus | 4 | 0.00391 | S | R | R |
| A. flavus | 1 | 0.00391 | S | R | S |
| A. flavus | 3 | 0.00195 | S | R | R |
| A. flavus | 6 | 0.00195 | S | R | S |
| A. flavus | 1 | 0.00098 | S | R | R |
| A. flavus | 2 | 0.00098 | S | R | S |
| A. flavus | 1 | 0.00049 | S | R | R |
| A. flavus | 1 | 0.00049 | S | R | S |
| Environmental isolates (18) | 18 | 0.00781 | S | R | S |
| A. flavus | 1 | 0.00781 | S | R | S |
| A. flavus | 4 | 0.00391 | S | R | R |
| A. flavus | 6 | 0.00391 | S | R | S |
| A. flavus | 1 | 0.00195 | S | R | R |
| A. flavus | 6 | 0.00195 | S | R | S |
| Total | 38 | - | 38S | 38R | 23S/15R |

LUL, Luliconazole; VOR, Voriconazole; AMP, Amphotericin B; CAS, Caspofungin; R, Resistant; S, Sensitive mL has shown the very high potent activity against clinical and environmental *A. flavus* strains. Similarly, in a study by Mahdavi-Omran et al. luliconazole showed the highest sensitivity to *A. flavus* strains in comparison with voriconazole, caspofungin and amphotericin B (7). Although, they found very low MIC_{GM} (0.008 μg/mL) for tested isolates, but our MIC_{GM} was highly low (MIC_{GM} 0.00288 μg/mL) for both sources, otomycosis and environmental isolates.
In our study all 38 tested isolates have shown that sensitive to voriconazole with the ECV ≤ 2 µg/ml. Many supportive studies have shown that A. flavus to be sensitive to voriconazole, like Denardi et al. and Mahdavi-Omran et al. which have reported MIC_{GM} values 0.871 and 0.27 µg/ml respectively ([7], [11]). Moreover, in a study by Borman et al. only 0.7% of A. flavus isolates were resistant to voriconazole ([10]) whereas all tested isolates by Varotto et al. were sensitive to voriconazole ([35]).

Echinocandin resistance is uncommon among A. flavus isolates. Diekema et al. Bedin Denardi et al. and Khodavaisy et al. have been reported excellent in vitro activity of caspofungin against clinical and environmental isolates of A. flavus ([11], [12], [28]). They found that all isolates had MEC_{90} lower than presented epidemiologic cutoff values. In our study the unexpected results, MEC ≥ 0.5 µg/ml for 10 clinical and 5 environmental isolates obtained for caspofungin. It seems that the source of isolates is effective on antifungal susceptibility. In this study, there was not any statistically significant difference between clinical and environmental strains and resistant to caspofungin (P = 0.161713).

Our results indicated that all isolates of A. flavus exhibited MICs ≥ 8 µg/ml against amphotericin B hence according to presented ECV all isolates were resistant to amphotericin B. Reichert Lima et al. have been reported that the 87% of A. flavus isolates from patients had MIC values ≥ 2 µg/ml and resistant to amphotericin B (8).

CONCLUSION

In conclusion, the analysis of our data clearly indicated that luliconazole (with MIC_{GM} 0.00244 µg/ml for clinical and 0.00336 µg/ml for environmental isolates) had the highest in vitro activity against A. flavus strains. Furthermore, voriconazole and then caspofungin appeared to be good antifungal drugs against A. flavus with an acceptable rate of resistant isolates (15 isolates to caspofungin).

ACKNOWLEDGEMENTS

We would like to thank the Department of Medical Mycology, Ahvaz Jundishapur University of Medical Sciences for their support. This study supported by Infectious and Tropical Diseases Research Centre, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences (OG: 9812).

REFERENCES

1. Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid 2014;9:113-124.
2. Abastabar M, Rahimi N, Meis JF, Aslani N, Khodavaisy S, Nabili M, et al. Potent activities of novel imidazoles lanconazole and luliconazole against a collection of azole-resistant and -susceptible Aspergillus fumigatus strains. Antimicrob Agents Chemother 2016;60:6916-6919.
3. Koga H, Nonjoh Y, Kaneda H, Yamaguchi H, Tsuboi R. Short-term therapy with luliconazole, a novel topical antifungal imidazole, in guinea pig models of tinea corporis and tinea pedis. Antimicrob Agents Chemother 2012;56:3138-3143.
4. Gupta AK, Dagle D. A critical appraisal of once-daily topical luliconazole for the treatment of superficial fungal infections. Infect Drug Resist 2016;9:1-6.
5. Zargaran M, Taghipour S, Kiasat N, Aboualigalehdari E, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A, et al. Luliconazole, an alternative antifungal agent against Aspergillus terreus. J Mycol Med 2017;27:351-356.
6. Taghipour S, Kiasat N, Shafiei S, Halvaezadeh M, Rezaei-Matehkolaei A, Zarei Mahmoudabadi A. Luliconazole, a new antifungal against Candida species isolated from different sources. J Mycol Med 2018;28:374-378.
7. Omran SM, Taghizadeh-Armaki M, Zarrinfar H, Hedayati MT, Abastabar M, Mosarabzadeh V, et al. In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis. J Infect Chemother 2019;25:157-160.
8. Reichert-Lima F, Lyra L, Pontes L, Moretti ML, Pham CD, Lockhart SR, et al. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates. Mycoses 2018;61:360-365.
9. Vaezi A, Fakhim H, Arastehfar A, Shokohi T, Hedayati MT, Khodavaisy S, et al. In vitro antifungal activity of amphotericin B and 11 comparators against Aspergillus terreus species complex. Mycoses 2018;61:134-142.
10. Borman AM, Fraser M, Palmer MD, Szekely A, Houldsworth M, Patterson Z, et al. MIC distributions and evaluation of fungicidal activity for amphotericin b, itraconazole, voriconazole, posaconazole and caspofungin and 20 species of pathogenic filamentous fungi.
determined using the CLSI broth microdilution method. *J Fungi (Basel)* 2017;3:E27. 11. Bedin Denardi L, Hoch Dalla-Lana B, Pantella Kunz de Jesus F, Bittencourt Severo C, Morais Santurio J, Zanette R A, et al. *In vitro* antifungal susceptibility of clinical and environmental isolates of *Aspergillus fumigatus* and *Aspergillus flavus* in Brazil. *Braz J Infect Dis* 2018;22:30-36. 12. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfäffer MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. *J Clin Microbiol* 2003;41:3623-3626. 13. Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, et al. Molecular diagnosis of invasive aspergillosis and detection of azole resistance by a newly commercialized PCR kit. *J Clin Microbiol* 2017;55:3210-3218. 14. Ukai Y, Kuroiwa M, Kurihara N, Naruse H, Homma T, Maki H, et al. Contributions of yap1 mutation and subsequent atrf upregulation to voriconazole resistance in *Aspergillus flavus*. *Antimicrob Agents Chemother* 2018;62(11):e0216-18. 15. Siopi M, Pournaras S, Meletiadiis J. Comparative evaluation of sensititre yeastone and clsi m38-a2 reference method for antifungal susceptibility testing of *Aspergillus* spp. against Echinocandins. *J Clin Microbiol* 2017;55:1714-1719. 16. Sharma S, Venigalla BM, Naidu SK, Pidakala P. Primary cutaneous aspergillosis due to *Aspergillus tamarii* in an immunocompetent host. *BMJ Case Rep* 2013;2013:010128. 17. Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF. Invasive aspergillosis by *Aspergillus flavus*: epidemiology, diagnosis, antifungal resistance, and management. *J Fungi (Basel)* 2019;5:E55. 18. Kiakorjo K, Bagherpour Jamnani N, Khafri S, Mahdavi Omran S. Assessment of response to treatment in patients with otomycosis. *Iran J Otorhinolaryngol* 2018;30:41-47. 19. Taghizadeh-Armaki M, Hedaya MT, Ansari S, Omran SM, Saber S, Rafati H, et al. Genetic diversity and *in vitro* antifungal susceptibility of 200 clinical and environmental *Aspergillus flavus* isolates. *Antimicrob Agents Chemother* 2017;61(5):e00004-17. 20. Rudramurthy SM, Seyedmousavi S, Dhaliwal M, Chakrabarti A, Meis JF, Mouton JW. Pharmacodynamics of voriconazole against wild-type and azole-resistant *Aspergillus flavus* isolates in a nonneutropenic murine model of disseminated aspergillosis. *Antimicrob Agents Chemother* 2016;61(1):e01491-16. 21. Mosquera J, Warn P, Morrissey J, Moore C, Gil-La maignere C, Denning D. Susceptibility testing of *Aspergillus flavus*: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B *in vitro* and outcome *in vivo*. *Antimicrob Agents Chemother* 2001;45:1456-1462. 22. Odds F, Van Gerven F, Espinel-Ingroff A, Bartlett M, Ghannoum M, Lancaster M, et al. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi *in vitro* and antifungal treatment outcomes in animal infection models. *Antimicrob Agents Chemother* 1998;42:282-288. 23. Rodrigues P, Soares C, Kozakiewicz Z, Paterson R, Lima N, Venâncio A. Identification and characterization of *Aspergillus flavus* and aflatoxins. In *Microbiology Book Series – Communicating Current Research and Educational Topics* ed A Méndez-Vilas pp. 527–534 Badajoz: Formatex 2007. 24. Sharma C, Kumar R, Kumar N, Masih A, Gupta D, Chowdary A. Investigation of multiple resistance mechanisms in voriconazole-resistant *Aspergillus flavus* clinical isolates from a chest hospital surveillance in Delhi, India. *Antimicrob Agents Chemother* 2018;62(3):e01928-17. 25. Principe S, Siciliano I, Contessa C, Botta R, Garibaldi A, Gullino ML, et al. Characterization of *Aspergillus* section Flavi isolated from fresh chestnuts and along the chestnut flour process. *Food Microbiol* 2018;69:159-169. 26. CLSI (2017). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; 3rd ed. CLSI document M38-3rd. Wayne, PA: Clinical and Laboratory Standards Institute. 27. Watanabe S, Kishida H, Okubo A. Efficacy and safety of luliconazole 5% nail solution for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study. *J Dermatol* 2017;44:197-201. 28. Khodavaisy S, Badali H, Hashemi SJ, Aala F, Nazeri M, Nouripour-Sisakht S, et al. *In vitro* activities of five antifungal agents against 199 clinical and environmental isolates of *Aspergillus flavus*, an opportunistic fungal pathogen. *J Mycol Med* 2016;26:116-121. 29. Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiaa A, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. *Haematologica* 2017;102:433-444. 30. Xavier MO, Oliveira Fde M, Almeida V, Prolla G, Severo LC. Invasive *Aspergillus flavus* sinusitis: case report in a patient with biphenotypic acute leukemia. *Rev Inst Med Trop Sao Paulo* 2009;51:57-58. 31. Shokoohi GR, Badali H, Mirhendi H, Ansari S, Rezaei-Matehkolaei A, Ahmadi B, et al. Molecular diagnosis of *Aspergillus flavus* isolates in a nonneutropenic murine model of disseminated aspergillosis. *Antimicrob Agents Chemother* 2017;61(1):e00635-17.
32. Todokoro D, Suzuki T, Tamura T, Makimura K, Yamaguchi H, Inagaki K, et al. Efficacy of luliconazole against broad-range filamentous fungi including *Fusarium solani* species complex causing fungal keratitis. *Cornea* 2019;38:238-242.

33. Wiederhold NP, Fothergill AW, McCarthy DI, Tavakkol A. Luliconazole demonstrates potent *in vitro* activity against dermatophytes recovered from patients with onychomycosis. *Antimicrob Agents Chemother* 2014;58:3553-3555.

34. Hivary S, Fatahnia M, Halvaezadeh M, Zarei Mahmoudabadi A. The potency of luliconazole against clinical and environmental *Aspergillus Nigri* complex. *Iran J Microbiol* 2019;11:510-519.

35. Varotto E, Putti MC, Sgarabotto D, Cecchin D, De Corti F, Beltrame V, et al. *Aspergillus flavus* disseminated infection in paediatric acute lymphoblastic leukaemia: A case report. *Med Mycol: Open Access* 2016;3:1-5.